How Does Sorafenib Work? — The Mechanism Behind Nexavar

Sorafenib is approved in India for three cancer types: advanced liver cancer (hepatocellular carcinoma), advanced kidney cancer (renal cell carcinoma), and radioiodine-refractory differentiated thyroid cancer. Your oncologist will have told you which applies to you. The mechanism is the same across all three — blocking the kinase and angiogenesis pathways — but the reasons it is chosen, and what response looks like, differ by cancer type.

Sorafenib is taken twice daily by mouth, on an empty stomach — at least one hour before or two hours after a meal. Take it at roughly the same times each day. If you miss a dose, do not double up — skip it and continue with your next scheduled dose. Do not crush or split the tablets. If you vomit after taking a dose, do not take an extra one; contact your team if vomiting is persistent, as it may affect how much of the drug you are absorbing.

Significant hair loss is not a typical feature of sorafenib, unlike many chemotherapy drugs. Some thinning can occur, but the dramatic hair loss associated with cytotoxic chemotherapy is not expected. The side effect that more commonly affects appearance is hand-foot skin reaction — thickening and soreness on the palms and soles — which your team can help you manage early if you report it promptly rather than waiting for it to worsen.

A kinase is a protein that acts as a molecular switch inside or on the surface of a cell. When switched on, it passes a signal along a chain of other proteins — a signal that can tell a cell to divide, survive or grow new blood vessels. Cancer cells often have kinases that are stuck in the on position or that fire too readily. Sorafenib fits into several of these switches and blocks them, interrupting the chain of instructions before it reaches the cell's nucleus.

No. Sorafenib is a targeted therapy — specifically a kinase inhibitor — which is a different class from immunotherapy. Immunotherapy works by removing the brakes on your immune system so it can recognise cancer cells. Sorafenib works by directly blocking proteins that cancer cells and tumour blood vessels rely on for growth. The two approaches are mechanistically distinct, have different side-effect profiles, and are not interchangeable, though they may be considered alongside each other in certain situations.

The main tool is imaging — typically a CT scan or PET-CT scan — taken at intervals your oncologist will set out, usually after the first few months of treatment and periodically after that. Your team compares scans over time to see whether the tumour is stable, has shrunk, or has grown. Blood markers may also be tracked depending on your cancer type. How you feel day to day is not a reliable guide — some patients feel the burden of side effects while the cancer is being controlled, and some feel well while the drug is losing effect.